Skip to main content

Table 1 Baseline characteristics of the patients

From: Outcome of anticoagulation with rivaroxaban in patients with non-retrieved inferior vena cava filters for the prevention of filter thrombosis: a retrospective cohort study

  Rivaroxaban group Warfarin group P value
Number of subjects 114 88  
Mean age 60.1 ± 13.2 57.3 ± 12.6 0.130
Male/Female 65/49 54/34 0.534
Concomitant disease
 Hypertension 44(38.6%) 21(23.9%) 0.026
 Diabetes 18(15.8%) 7(8.0%) 0.094
 Coronary heart disease 10(8.8%) 6(6.8%) 0.610
 Cerebral infarction 11(9.7%) 4(4.6%) 0.170
Risk factors for VTE
 Transient risk factors 41(36.0%) 48(54.6%) 0.008
 History of VTE 25(21.9%) 9(10.2%) 0.028
 Cancer 28(24.6%) 16(18.2%) 0.276
 Thrombophilia 4(3.5%) 3(3.4%) 1.000
Type of VTE
 DVT only 98(86.0%) 82(93.2%) 0.103
 DVT and PE 16(14.0%) 6(6.8%)
Location of DVT
 Proximal 110(96.5%) 83(94.3%) 0.690
 Distal 4(3.5%) 5(5.7%)
Indication for IVCF insertion
 Contraindications to anticoagulation 46(40.3%) 34(38.7%) 0.476
 VTE with failure of anticoagulation 14(12.3%) 6(6.8%)
 Perioperative operation 19(16.7%) 20(22.7%)
 Thrombolysis 35(30.7%) 28(31.8%)
Filter type
 TrapEase filter (Cordis) 36(31.6%) 20(22.7%) 0.156
 OptEase filter (Cordis) 38(33.3%) 34(38.6%)
 G2 filter (Bard) 16(14.0%) 7(8.0%%)
 Aegisy filter (China) 24(21.1%) 27(30.7%)
Length of follow-up(months) 57.4 ± 20.8 62.2 ± 23.0 0.158